Reaction
Chylothorax reporting signals
As of the last recalculation, Chylothorax appears in 703 FAERS reports alongside 21 co-occurring drug terms. The strongest observed disproportionality signal is DASATINIB (PRR 171.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Dasatinib | 165 | 171.4 | 172.2 |
| Bosutinib | 15 | 50.5 | 50.6 |
| Imatinib | 27 | 47.1 | 47.2 |
| Atovaquone | 12 | 44.9 | 44.9 |
| Vincristine Sulfate | 27 | 28.3 | 28.4 |
| Amphotericin B | 11 | 26.4 | 26.4 |
| Pyrazinamide | 8 | 25.5 | 25.5 |
| Polyethylene Glycol | 9 | 24.9 | 24.9 |
| Polatuzumab Vedotin | 7 | 21.4 | 21.5 |
| Bendamustine Hcl | 11 | 21.3 | 21.3 |
| Ritonavir 100 Mg | 10 | 20.1 | 20.1 |
| Sirolimus | 9 | 20.0 | 20.0 |
| Darunavir | 10 | 19.8 | 19.9 |
| Everolimus Tablets | 11 | 19.7 | 19.7 |
| Rifampicin | 6 | 17.7 | 17.7 |
| Nilotinib | 16 | 16.4 | 16.4 |
| Tolvaptan | 6 | 12.3 | 12.3 |
| Obinutuzumab | 6 | 10.9 | 10.9 |
| Bendamustine Hydrochloride | 4 | 9.9 | 9.9 |
| Palivizumab | 4 | 7.7 | 7.7 |
| Crizotinib | 3 | 7.0 | 7.0 |